PAR 5.00% 19.0¢ paradigm biopharmaceuticals limited..

Ann: iPPS SIGNIFICANT OA PAIN REDUCTION AT 12 MONTHS, page-39

  1. 214 Posts.
    lightbulb Created with Sketch. 104
    Phase 2 studies are typically dose defining studies. We are just trying to do them concurrently to speed things up. How is it incompetence if they are doing what all pharma companies do?
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.